The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations for COVID-19 shots developed by Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) ...

Unlike BioNTech, Moderna's pipeline is nearly "all in" on mRNA assets. Most of them are infectious disease vaccines, particularly in COVID, flu, and RSV.

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday.

Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...

BioNTech SE BNTX and Moderna Inc MRNA are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic. Also Read: FDA Approves Updated ...